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OBJECTIVES: Acute promyelocytic leukemia (APL) is a distinct subtype of acute mye-
loid leukemia (AML) with approximately 1,000 to 1,500 new cases diagnosed each 
year in the United States (US). Trisenox (arsenic trioxide, ATO) is currently licensed 
for the treatment of patients with APL who are refractory to, or have relapsed from 
previous treatment with all-trans retinoic acid (ATRA) and anthracycline-based 
chemotherapy. This analysis evaluated the cost-effectiveness of ATO+ATRA in 
the treatment of newly diagnosed low-to-intermediate risk APL in adult patients, 
compared to two other widely used regimens: ATRA+Ara-C+chemotherapy, and 
ATRA+Idarubicin (AIDA). Cost-effectiveness was measured as incremental cost 
per quality-adjusted life year (QALY) gained and per incremental cost per life year 
(LY) saved from a third-party payer perspective in the US. METHODS: A Markov 
cohort model with monthly cycles and four health states (1st-line stable disease, 
2nd-line stable disease, 2nd-line disease event, and dead) was developed. Patients 
in the model begin treatment at age 45 and were followed until death. Eight 
months duration of ATO+ATRA was compared to either 15 months of ATRA+Ara-
C+chemotherapy or 33 months of AIDA. Efficacy data (event-free survival.overall 
survival) were obtained from key clinical trials. Quality of life/health utility data 
were obtained from the literature. Costs were obtained from standard US data 
sources. Transition probabilities were estimated by calibrating the model to event-
free and overall survival Kaplan-Meier curves for each treatment. Deterministic 
and probabilistic sensitivity analyses were conducted. RESULTS: Compared to 
ATRA+Ara-C+chemotherapy, ATO+ATRA had incremental cost effectiveness ratios 
of $5,900/QALY gained and $4,800/LY saved. ATO+ATRA weakly dominated AIDA 
(had a lower incremental cost-effectiveness ratio and more QALYs and LYs) in newly 
diagnosed patients. The results were robust to sensitivity analysis. CONCLUSIONS: 
The shorter and better-tolerated regimen of ATO+ATRA is a highly cost-effective 
strategy compared to ATRA+Ara-C+chemotherapy or AIDA in the treatment of newly 
diagnosed low-to-intermediate risk APL patients.
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OBJECTIVES: In ALSYMPCA, radium-223+BSoC significantly prolonged overall sur-
vival by 3.6 months (HR= 0.70; 95% CI, 0.58-0.83; P< 0.001). Analysis of prospectively 
collected medical resource utilization (MRU) data from ALSYMPCA demonstrated 
that radium-223+BSoC vs BSoC reduced overall MRU, including number of hospi-
talization days/patient/year (8.1 vs 14.6; P< 0.001). An existing cost-effectiveness 
analysis (CEA) model was modified by incorporating the prospective MRU data 
from ALSYMPCA to evaluate their effect on estimated cost-effectiveness of radium-
223+BSoC vs placebo+BSoC in Canada. METHODS: A Markov model was developed 
with 5 health states, reflecting disease progression and SSEs. The Canadian payer 
perspective was used. Quality of life data were from ALSYMPCA; cost inputs were 
from recognized Canadian sources. Costs and outcomes were discounted at a 5% 
annual rate. Model time horizon was 5 years. RESULTS: Incorporating MRU data 
reduced the incremental cost estimate by $11,065 relative to CEA without MRU data 
and improved the incremental cost-effectiveness ratio for radium-223+BSoC vs 
placebo+BSoC by ~35% to $73,408 ($20,098 incremental cost, 0.274 quality-adjusted 
life years [QALYs] gained), substantially lower than the frequently referenced, 
although not explicitly stated, Canadian cancer drug threshold ($100,000/QALY). 
Sensitivity analyses demonstrated robustness of cost-effectiveness results. Patient 
management costs were affected primarily by differential hospital utilization 
between treatment groups. CONCLUSIONS: Including directly observed MRU data 
in this model markedly improved the impact of radium-223 vs modeled benefits 
alone, confirming its cost-effectiveness as a treatment for CRPC with symptomatic 
bone metastases and no visceral metastases. Reduced hospital utilization with 
radium-223 may be driven by delays in time to symptomatic skeletal event (SSE) 
and reduced hospitalization days/patient/year after SSE (Cislo et al. ASCOQCS 2014).
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OBJECTIVES: To evaluate cost-effectiveness of different HPV vaccination as alterna-
tives or additions to the current screening program to prevent and control cervical 
cancer in Mainland China. METHODS: A Markov model was developed for a cohort 
of 100,000 12-year-old girls to simulate the natural history of low risk and high risk 
to HPV infection and its progress to cervical cancer or genital warts. Three recom-
mended screening (protocol 1. Liquid-based cytology test + HPV DNA test; protocol 
2. Pap smear cytology test + HPV DNA test; protocol 3. Visual inspection with acetic 
acid) and two types of HPV vaccination programs (bivalent and quadrivalent vac-
cines) were incorporated to the two kinds of HPV vaccines. Input data were obtained 
from literature review, national databases, and a field study. Sensitivity analyses 
tive. METHODS: We compared ipilimumab treatment for advance melanoma 
with other drugs for advanced cancer that met inclusion criteria including: (1) 
positive phase three study with overall survival as primary or secondary aim, 
(2) authorized by Chilean government agency, and (3) verifiable price in the pri-
vate market. We performed a cost – efficacy analysis, using local prices obtained 
from published local sources to calculate an average cost to progression. Time to 
progression was obtained from published clinical trials. Mean overall survival 
improvement was used as the efficacy metric. Cost – efficacy outputs were plot-
ted and compared. All costs are presented in 2014 USD. Additionally, a survey to 
Chilean oncology specialist was designed to obtain qualitative information about 
their experience(s) with ipilimumab for the treatment of metastatic melanoma 
patients in Chile. RESULTS: Nineteen drugs met inclusion criteria with 28 advance 
cancer indications. The average cost per month of mean survival improvement was 
estimated at $24,802 (range 1,737 – $91,256). We estimated the cost per additional 
month of mean survival improvement at $13,122 and $14.843 for first and second 
line treatment with ipilimumab respectively. Based on the survey, local expert 
opinion unanimously stated that ipilimumab is the best treatment alternative for 
patients with advanced melanoma. CONCLUSIONS: Compared with other inno-
vative drugs for the treatment of advanced cancers, the cost per mean survival 
improvement with ipilimumab was below the average market value and may 
provide good value for money from a third payer perspective in Chile. Based on 
the survey, specialists noted ipilimumab as the best treatment option for Chilean 
patient with advanced melanoma.
PCN71
BEvACizumAB for froNt-liNE trEAtmENt of EPithEliAl ovAriAN, 
fAlloPiAN tuBE or PrimAry PEritoNEAl CANCEr PAtiENts With high 
risk of rElAPsE: A Cost EffECtivE oPtioN for CANAdiAN PAtiENts
Ghatage P.1, Wright E.J.2, Martin Nunez I.2, Yin L.2, Ray J.3
1University of Calgary, Calgary, AB, Canada, 2Hoffmann-La Roche, Mississauga, ON, Canada, 3F. 
Hoffmann-La Roche, Basel, Switzerland
OBJECTIVES: In the ICON7 randomized controlled trial, Oza et al. reported that 
the 502 front line ovarian cancer patients who were at a high-risk of relapse, that 
is patients with stage III suboptimal debulking, stage III unresectable or stage IV 
disease, could benefit most effectively from the addition of bevacizumab (7.5mg/kg) 
to chemotherapy (carboplatin, paclitaxel), compared to chemotherapy alone in the 
front line setting. The objective of this study is to investigate the cost effectiveness 
(CE) of this proposed change in treatment practices. METHODS: Long-term PFS and 
OS were predicted using log-logistic time-to-event parametric functions over a time 
horizon of 10 years. Canadian PFS health state utility values were obtained from the 
mapping of EQ5D scores from ICON7’s high risk patient population. Post progression 
utility values were derived from Naik et al (2014) Canadian study. The cost inputs, 
including standard resource use practices, for this CE model were informed from 
public sources, gynecological oncology experts and ICON7. An annual 5% discount 
rate was applied to both efficacy and costs. A probabilistic sensitivity analysis (PSA) 
as well as one-way sensitivity analyses were conducted. RESULTS: The ICON7 high-
risk patients receiving bevacizumab plus chemotherapy had a mean LY gain of 5.8 
months compared to patients on chemotherapy alone, and a mean QALY gain of 
4.5 months. This resulted in an ICER of $74,084CAD per LY gained and $96,261CAD 
per QALY gained. 55% PSA simulation of the QALY ICERs were at $100,000CAD or 
less. CONCLUSIONS: Although no formal willingness-to-pay threshold exists for 
health technology assessments in Canada, $100,000CAD has been estimated for 
oncology drugs. At a $100,000CAD threshold, bevacizumab in addition to chemo-
therapy provides a cost-effectiveness alternative for high-risk patients (i.e. stage 
III suboptimal debulking, stage III unresectable or stage IV) with ovarian cancer in 
the front line setting.
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OBJECTIVES: This study examined indirect costs in terms of productivity loss 
among patients who received eribulin vs. other commonly used chemotherapies 
in the treatment of metastatic breast cancer (MBC). METHODS: The MarketScan 
Health and Productivity Management Database (2008-2012) was used. Patients 
who initiated eribulin, or received single-agent gemcitabine/capecitabine/vinorel-
bine as the last chemotherapy during the index period (July 2008-Nov 2012) 
were defined as each corresponding study cohort. Adult MBC patients eligible 
for ≥ 1 month employee benefits of short-term disability (STDI) were identified. 
Difference in STDI days was compared between study cohorts using Wilcoxon-
rank-sum-test. STDI-related costs were estimated by multiplying leave days by 
median weekly wages. Two-step generalized linear models were used to estimate 
adjusted indirect costs by controlling for age, payer, region, comorbidities, prior 
chemotherapy, and hormone therapy. RESULTS: A total of 43 patients receiving 
eribulin, 99 gemcitabine, 54 vinorelbine, and 303 capecitabine were eligible for 
STDI (mutually exclusive). Eribulin patients had either similar (vs. gemcitabine 
or vinorelbine) or more (vs. capecitabine) chemotherapy agents prior to initiat-
ing index treatment. Eribulin patients had either numerically lower or similar 
STDI days per-patient-per-month compared to those receiving other therapies 
(6.2±10.8 vs. 8.8±11.0 [gemcitabine], P= .055; 7.1±10.3 [vinorelbine], P= .201; 6.1±9.2 
[capecitabine], P= .295). In addition, eribulin (vs. gemcitabine) patients were less 
likely to have any STDI leave (30% vs. 53%, P= .014). The adjusted mean indirect 
costs associated with STDI per-patient-per-month were $720 (95% CI: $470-$1,102), 
$944 (95% CI: $595-$1,175), $837 (95% CI: $744-$1,198) and $635 (95% CI: $536-
$753) for eribulin, gemcitabine, vinorelbine and capecitabine patients, respec-
tively. CONCLUSIONS: Productivity loss, as measured by utilization of STDI and 
associated costs, tended to be lower in MBC patients treated with eribulin vs. 
gemcitabine and similar to vinorelbine or capecitabine.
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setting, there is a need for additional information on the clinical and economic 
impact of idelalisib to inform decisions about utilization, coverage, and reim-
bursement. OBJECTIVES: The objective of this study was to evaluate the cost-
effectiveness of idelalisib plus rituximab versus rituximab alone from a payer’s 
perspective. METHODS: We developed a partition survival model to evaluate ide-
lalisib plus rituximab versus rituximab alone. The model included three health 
states – Pre-Progressed, Progressed, and Death. The pivotal trial Study 116 (Furman 
et al., 2014) served as the basis for this study by providing data on Progression-
Free-Survival (PFS) and Overall-Survival (OS), dosing, and adverse events. We used 
longer-term data from a trial of bendamustine plus rituximab in CLL plus Weibull 
cumulative distribution functions to extrapolate incomplete PFS and OS curves. 
Cost data was derived from Wolters Kluwer Health, Centers for Medicare and 
Medicaid Services data, and publicly available literature. One-way and probabilistic 
sensitivity analyses were performed to evaluate uncertainty. We used a lifetime 
horizon, payer perspective, and a 3% discount rate. RESULTS: Total costs were 
$585,493 and QALYs were 3.34 for the idelalisib plus rituximab group, while total 
costs were $66,698 and QALYs were 1.20 for the rituximab alone group. This yielded 
an incremental cost-effectiveness ratio of $242,884/QALY. The result was most 
sensitive to changes in the hazard ratio for death and idelalisib drug costs. The 
probability that idelalisib was cost-effective was 1% at both a willingness to pay 
of $100,000/QALY and $150,000/QALY. CONCLUSIONS: Idelalisib plus rituximab 
does not appear to be cost-effective since it greatly exceeds the commonly cited 
thresholds of $100,000/QALY and $150,000/QALY. However, it is in line with other 
commonly used treatments in cancer.
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OBJECTIVES: Mortality associated with the lung cancer is maximum among all 
forms of cancer in the US. Among all lung cancer patients, 85% have non-small 
cell lung cancer (NSCLC). Of these NSCLC patients, 5% are EML4-ALK gene positive 
patients. In these patients, standard therapy [platinum doublet (cisplatin and gem-
citabine) as first-line therapy, pemetrexed as second-line therapy, and erlotinib as 
third-line therapy] has shown plateau effect. In 2014, FDA has approved Ceritinib as 
a first line therapy based on the results from phase one study, under the orphan drug 
category for ALK+NSLCC. Study aims to evaluate the cost-effectiveness of EML4-ALK 
fusion targeted ceritinib treatment as compare to treatment by standard therapy 
among ALK+NSCLC patients in the US. METHODS: A decision analytic model with 
the embedded Markov model was developed to compare the lifetime benefits in 
terms of quality adjusted life years [QALYs] and direct medical costs of the treatment 
strategies for patients with advanced NSCLC. Progression free survival rate during 
each treatment alternatives, rates of adverse events, mortality rates, and utility 
values on standard therapy and ceritinib were obtained from published literature. 
Cost inputs were based on 2013 Medicare reimbursement rates. Primary outcome of 
incremental cost effectiveness ratio (ICER) was estimated as an incremental cost of 
treating with Ceritinib per QALY gained. USD 100,000 was considered as the willing-
ness to pay threshold. RESULTS: The use of EML4-ALK targeted ceritinib treatment 
for EML4-ALK–positive advanced NSCLC results in added benefits (0.09 QALYs) and 
extra costs ($1897.82) for the average patient with NSCLC. The ICER was $21,263 for 
per QALY gained. CONCLUSIONS: Study suggests that the treatment by Ceritinib 
compared to the treatment by standard therapy alone is a cost-effective strategy 
based upon the decision analysis model. Study limitation includes non-inclusion 
of the cost of EML4-ALK gene testing, which could change the total treatment cost 
significantly.
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OBJECTIVES: Sorafenib is the first product approved for treatment of RAI refractory 
locally advanced/metastatic DTC patients. This study was conducted in order to 
analyze cost-effectiveness of sorafenib for treatment of patients with RAI refrac-
tory locally advanced/metastatic DTC in Turkey. METHODS: A cohort partition 
model assigning patients to one of three health states according to the proportion 
of patients who are progression-free, progressed, or dead in each 28-days cycle 
was adapted to Turkish setting. The incremental cost-effectiveness ratios (ICER) 
were calculated per quality-adjusted life years (QALYs) and life-years (LYs) gained. 
Turkish payer’s perspective was taken and time-horizon was set as patient’s lifetime 
(maximum 30 years). Sorafenib was compared to the best supportive care (BSC) 
within the model since there are no agents for treatment of patients on this stage 
of the disease. Essential clinical inputs were derived from DECISION trial and local 
resource-utilization data were based on expert opinions through an expert panel. 
Sensitivity of the results was evaluated in terms of key inputs by deterministic one-
way and probabilistic sensitivity analyses. All costs were calculated in Turkish Liras 
(TL) and converted to USD using TL/USD currency rate as 2.2 (mid-2014). RESULTS: 
Total cost of sorafenib-treated patients is 24,384 USD higher compared to BSC. 
Besides, sorafenib is associated with increments of 1.29 LYs and 0.80 QALYs com-
pared to BSC. The ICER of sorafenib per LYs and QALYs gained compared to BSC 
were determined as 18,851 USD and 30,485 USD respectively. One-way sensitivity 
analysis demonstrated that results are not sensitive to the changes in model inputs 
were performed on key variables and different vaccination scenarios. RESULTS: 
With 20% screen coverage and 20% vaccine coverage, quadrivalent vaccine plus 
screening by protocol 2 had the most attractive cost-effectiveness ratio ($6,691 per 
QALY saved) compared to when using a willingness to pay (WTP) for a QALY thresh-
old of $22,433 (three times of GDP per capita in China). The bivalent vaccine and 
its combination with the screening program could reduce much more incidence 
and mortality of cervical cancer compared to the quadrivalent vaccine, while the 
cost per QALY acquired of the quadrivalent vaccine is lower. The combined strate-
gies are cost-effective compared to the counterparts of vaccination alone and can 
achieve much more health benefits compared to screening alone. The coverage of 
the screening and the vaccination serve as a crucial factor of variations in the cost-
effectiveness of different strategies. CONCLUSIONS: HPV vaccinations integrated 
into the current screening programs are cost-effectiveness strategies, and should be 
considered a potential strategy to reduce disease burden of cervical cancer in China. 
Selection of the appropriate strategy can be flexible for policy makers, because of 
geographical and socioeconomic diversities.
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Abiraterone acetate (Abi) therapy showed survival and clinical benefits in the treat-
ment of metastatic castration-resistant prostate cancer (mCRPC) in phase III trials. In 
Quebec, Abi reimbursement was approved for docetaxel-naïve and refractory patients 
in 2014 and 2012, respectively.OBJECTIVES: Evaluated the cost-effectiveness and sur-
vival impact of Abi treatment in the management of CRPC post-docetaxel. METHODS: 
The study cohort was selected from the public healthcare insurance programs: Régie 
de l’Assurance Maladie du Québec (RAMQ) and Med-Echo databases. It consisted 
of patients with CRPC starting chemotherapy or abiraterone treatments beteween 
2009-2010 (docetaxel), defined as pre-Abi era, and 2012-2013 (docetaxel+Abi), defined 
as Abi era. Survival was evaluated by Kaplan-Maier and the difference in survival 
between pre-Abi and Abi eras by log-rank test. Association between Abi exposure 
and survival was evaluated by cox proportional hazards model adjusted for co-vari-
ables. The incremental cost-effectiveness ratio was obtained by dividing changes in 
costs (Docetaxel alone, Docetaxel+Abi) and survival in the two periods. RESULTS: 
Survival was significantly increased by the addition of Abi to CRPC management. 
Mean survival were 11.47 (±0.6; N= 115) vs 15.26 (± 0.85; N= 67) months in the pre-Abi 
vs Abi era (p< 0.001). Mean treatment duration for Abi was 163 days (±108.7) and for 
chemotherapy during Abi period was 4.4 cycles (±3.1) and 4.6 clycles in the pre-Abi 
era (±4.2). The adjusted harzard ratio when comparing pre-Abi vs Abi era was 1.32 
(95%CI 0.98-1.78). The cost per patient for docetaxel treatment was $3,680 and for 
docetaxel+Abi was C$49,650. As expected, the addition of Abi resulted in a cost incre-
ment of C$45,970/patient. The incremental cost-effectiveness ratio was C$145,569 per 
life-year gained. CONCLUSIONS: Our real-life study indicates that patients receiving 
Abi plus docetaxel had a survival benefit when compared to chemotherapy alone. 
Addition of Abi was associated with an important increase in CRPC therapy costs.
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OBJECTIVES: The objective of this study was to estimate Incremental Cost-
Effectiveness Ratio (ICER) of utilizing eribulin for Metastatic Breast Cancer 
(MBC) in Spain for the second line (2L) treatment of HER2 negative (HER2NEG) 
patients. METHODS: Eribulin is indicated for the treatment of patients with locally 
advanced or MBC who have progressed following one prior chemotherapeutic regi-
men (FOPC). An economic model was developed to evaluate the cost-effectiveness 
of eribulin in HER2NEG MBC FOPC population in Spain. The data on progression 
free survival and overall survival was derived from randomized clinical trial of 
eribulin against capecitabine (study 301). A five year partitioned survival model was 
developed to estimate the ICER of the patients in this sub-group. Health state utility 
data was obtained by mapping quality of life collected in study 301 to EQ-5D using 
validated algorithm. Frequencies of adverse events and utilization of direct medical 
resources were also obtained from study 301. Local Spain tariffs were applied for all 
costs i.e. drug, administration, adverse event treatment, and direct medical costs 
including hospitalization, physician visits, end of life and palliative care. RESULTS: 
Incremental life years (LYs) and Quality Adjusted Life Years (QALYs) gained by these 
patients were 0.26 and 0.23 respectively. At a cost of eribulin of € 320 per vial, the 
ICERs per LY and QALY saved were € 32,865 and € 36,951 respectively. Sensitivity 
analysis results were also consistent with the basecase findings. CONCLUSIONS: 
According to reviewed HTA decisions in the past, eribulin was found to be cost-
effective in 2L HER2NEG populations. Given the limited number of effective thera-
peutic options available to these patients, cost effective eribulin represents a valid 
option for optimizing the treatment pathways.
PCN79
idElAlisiB Plus rituximAB vErsus PlACEBo Plus rituximAB for 
rElAPsEd ChroNiC lymPhoCytiC lEukEmiA: A Cost-EffECtivENEss 
ANAlysis
Yu J.S.1, Seal B.2, Carlson J.J.1
1University of Washington, Seattle, WA, USA, 2Bayer HealthCare Pharmaceuticals, Whippany, NJ, 
USA
BACKGROUND: No published economic evidence currently exists with regards 
to idelalisib for relapsed chronic lymphocytic leukemia (CLL). Given its recent 
approval, comparator products on the market, and the high cost of care in this 
